Improving PrEP Implementation Through Multilevel Interventions: A Synthesis of the Literature
There are many challenges to accessing PrEP and thus low uptake in the United States. This review (2007–2017) of PrEP implementation identified barriers to PrEP and interventions to match those barriers. The final set of articles (n = 47) included content on cognitive aspects of HIV service providers and individuals at risk for infection, reviews, and case studies. Cognitive barriers and interventions regarding patients and providers included knowledge, attitudes, and beliefs about PrEP. The “purview paradox” was identified as a key barrier—HIV specialists often do not see HIV-negative patients, while primary care physicians, who often see uninfected patients, are not trained to provide PrEP. Healthcare systems barriers included lack of communication about, funding for, and access to PrEP. The intersection between PrEP-stigma, HIV-stigma, transphobia, homophobia, and disparities across gender, racial, and ethnic groups were identified; but few interventions addressed these barriers. We recommend multilevel interventions targeting barriers at multiple socioecological domains.
KeywordsPrEP implementation PrEP integrative review HIV prevention Continuum of care
Existen muchos desafíos para acceder a PrEP y, por lo tanto, poca aceptación en los Estados Unidos. Esta revisión (2007-17) de la implementación de PrEP identificó las barreras a la PrEP y las intervenciones para hacer coincidir esas barreras. El conjunto final de artículos (n = 47) incluyó contenido sobre los aspectos cognitivos de los proveedores de servicios de VIH y las personas en riesgo de infección, revisiones y estudios de casos. Las barreras cognitivas y las intervenciones con respecto a los pacientes y proveedores incluyeron el conocimiento, las actitudes y las creencias sobre la PrEP. La “purview paradox” se identificó como una barrera clave: los especialistas en VIH a menudo no ven pacientes VIH negativos, mientras que los médicos de atención primaria, que a menudo ven pacientes no infectados, no están capacitados para proporcionar PrEP. Las barreras de los sistemas de salud incluyen la falta de comunicación, financiación y acceso a la PrEP. Se identificó la intersección entre el estigma de la PrEP, el estigma del VIH, la transfobia, la homofobia y las disparidades entre los grupos de género, raciales y étnicos; pero pocas intervenciones abordaron estas barreras. Recomendamos intervenciones multinivel dirigidas a las barreras en múltiples dominios socioecológicos.
In 2011–2012, the United States Centers for Disease Control and Prevention (CDC) launched the high-impact HIV prevention (HIP) approach to respond to research showing that antiretroviral therapy (ART) reduces HIV transmission by lowering viral load in the bloodstream . In 2012, the use of ART emerged as the dominant strategy for HIV treatment and prevention —research predicted reduction of sexual transmission in HIV-serodiscordant couples by more than 96% . High-impact interventions—HIV testing, linkage to care, and HIV viral suppression with ART—constitute key steps of the HIV Continuum of Care, recommended by the World Health Organization [4, 5]. HIP promotes HIV pre-exposure prophylaxis (PrEP). PrEP has been traditionally considered as once daily oral dosing of ART prescribed to individuals at risk for HIV infection. The Food and Drug Administration (FDA) approved Truvada™ [Emtricitabine/Tenofovir Disoproxil Fumarate (TDF/FTC)] in 2012 as a PrEP strategy that reduced the risk of HIV acquisition by 73% among adult men who have sex with men (MSM) and transgender women who took it 90% of the time ; with greater efficacy (up to 99%) for individuals with higher rates of adherence and increased concentrations among serodiscordant heterosexual couples [7, 8].
Herein, the steps patients and providers must take to follow policies governing access to PrEP and to navigate healthcare systems will be referred to as “PrEP implementation.” PrEP implementation may appear to be an easy and effective way to stop HIV transmission; however, there are many challenges to accessing and adhering to PrEP, as reflected in low levels of PrEP uptake in the US [9, 10]. Concern over rates of adherence and retention have been reported in PrEP care in clinical trials and “real world” PrEP demonstration projects [11, 12]. Racial and gender disparities have also been identified, including disproportionately low PrEP uptake among Black MSM . Research regarding low access, uptake, and adherence to PrEP in the US has focused mostly on breakdowns in the healthcare systems implementing PrEP, lack of provider awareness and willingness to prescribe PrEP [9, 14], and unfavorable patient and community attitudes about PrEP [15, 16]. Our aim therefore is to comprehensively review this literature, focusing on how barriers to PrEP uptake might affect both individual actors and healthcare systems.
Barriers to PrEP implementation occur across gender, racial, and ethnic groups. Various interventions have been proposed to solve this public health problem, including those targeting different domains of prevention and care—patients, providers, and healthcare systems. Nonetheless, proposed interventions to improve PrEP implementation may vary across the fields of medicine, nursing, social work, public health, and the social sciences. Therefore, this review included papers in all these disciplines and sought to identify barriers to PrEP and the interventions available that specifically matched those barriers. We focused specifically on PrEP implementation in the US and on implementation issues faced by at-risk individuals and HIV service providers, the agency settings in which services are offered, and the policies that guide HIV service provision. “HIV service providers” in this context refer to counselors, educators, case managers and others who provide HIV testing, linkage to care, and other services, as well as HIV-care providers. Our review aims to improve HIV-prevention strategies nationwide by demonstrating how to confront identified barriers with interventions that might improve access, uptake, and adherence to PrEP.
Literature Review Conceptual Approach
Integrative Review Model
We adopted an integrative review model to provide a more comprehensive understanding of PrEP implementation in various domains of reference . Our review focuses on a period (January 2007 to June 2017) that included the emergence of the concept of the HIV Continuum of Care and the high-impact prevention (HIP) approach, followed by large-scale clinical trials (e.g., the iPrEx study) [6, 25, 26], and the subsequent approval by the FDA (in July 2012) of the provision of PrEP in service settings .
Literature Search Terms
We used combinations of search terms in ArticlesPlus, a comprehensive database of peer-reviewed clinical and academic journals in medicine, public health, social work, nursing, pharmacy, and law, hosted by the University of Michigan Library. Our combination of search terms, including truncation operators (*), was as follows:
Subject Terms: (HIV OR HIV/AIDS OR AIDS) AND
Title: (PrEP OR “Pre-Exposure Prophylaxis”) OR [(antiretroviral* OR pharmaceutical*) AND prevent*)] AND
All Fields: [(worker* OR practitioner* OR provider*) AND (linkage* OR linking OR referral* OR implementation OR uptake)]
Inclusion and Exclusion Criteria
We included peer-reviewed papers presenting research on PrEP implementation, PrEP in the US, HIV service workers, practitioners, medical or social-service providers, and service agencies. We excluded papers that exclusively addressed the attitudes and beliefs of individuals targeted by HIV-prevention programs; however, we did include studies focused on the attitudes and beliefs of potential PrEP patients specifically related to the effective implementation of PrEP. We also included studies focused on attitudes and beliefs of HIV-prevention providers. We restricted this review to research in the US because of the unique historical response to HIV/AIDS in the US and the particular attributes of its healthcare system, and to yield results applicable to PrEP implementation in the US.
Procedures for Article Selection
Our analysis focused on identifying barriers to PrEP and the interventions aligned with those barriers. To enhance the rigor of our analysis, we adopted the following techniques: purposive sampling; grounded theory; and multidisciplinary collaborative interpretation .
We borrow the term “purposive sampling” to describe the procedures we used (described above) to select the articles for this integrative review—specific search terms, inclusion and exclusion selection criteria, and procedures for article selection.
Our analysis reflects a modified version of grounded theory  in which how we selected the final set of articles for analysis, as well as how we read/interpreted the articles, was based on the content we found and grounded in our experiences as both HIV/AIDS researchers and practitioners in community settings offering HIV-related services. We concurred on definitions, recurring terms, and barriers and solutions to PrEP implementation before beginning analysis. We also used a conceptual framework to guide how we identified and aligned barriers with interventions in the selected articles.
Multidisciplinary Collaborative Interpretation
Summary of barriers to, and interventions to improve, PrEP implementation
Conceptual domain and intervention level
Barriers to PrEP implementation
Interventions matching specific barriers
Individual and Relationships Domains:
Lack of training in PrEP provision
Disagreement/uncertainty about appropriate PrEP patients
Concerns/uncertainty about insurance coverage for PrEP
Attitudes and beliefs
Biases against patients’ race and sexual behaviors
Concerns about PrEP efficacy, toxicity, and resistance
Concerns about patients’ disinhibition and risk compensation leading to lack of adherence/compliance
Improved education of potential PrEP providers
Development of trainings and interventions to assist providers in identifying appropriate PrEP candidates
Attitudes and beliefs
Development and delivery of trainings to increase provider “cultural competency,” including trans- and gender-affirming care
Interventions to identify and disrupt provider-held stereotypes about potential PrEP users
Individual and Relationships Domains:
Low awareness of PrEP and low demand for PrEP
Attitudes and beliefs
Side effects; effectiveness; toxicities; interaction with feminizing hormones
Managing multiple health concerns and PrEP side effects
Prioritization of care for current conditions (e.g., pain or stress) above HIV prevention
Prioritization of gender-affirming feminizing hormone therapy
Distrust of medical system: structural racism, transphobia, and negative experiences
Competing priorities during periods of substance use
Diminished concern for prevention with intimate partners
Concerns about HIV-reporting systems, including potential insurance implications of a positive HIV result
Unwillingness to discuss PrEP with primary care providers
Increased education and counseling to increase PrEP knowledge
Attitudes and beliefs
Development of supportive behavioral interventions (e.g., risk-reduction, medication-adherence, and retention counseling)
Assistance in navigating the healthcare system, including accessing health insurance and co-pay assistance
Referrals of patients with mental-health, substance-use, or “social” issues (e.g., housing insecurity) to social workers or community resources
Community and Policy
Communication and awareness
Lack of effective messaging about PrEP
Lack of communication between healthcare providers and community-based organizations
Limited health budgets to sustain PrEP programs
Lack of insurance coverage and financial-assistance programs
Capacity & access
Lack of focus on “nonprescribing service providers”
Purview paradox: neither HIV specialists nor PCPs consider PrEP implementation within their clinical domain
Lack of training, referral systems, or established reimbursement levels for care and drugs
Legal constraints to providing PrEP for youth, including mandates to involve parental figures in working with minors
Lack of access to care: inadequate transportation; inflexible work schedules; inconvenient locations dispensing PrEP
Time constraints on medical appointments
Lack of medical insurance and limited insurance networks
Lack of patient confidence and perseverance to access care
Particular constraints of Truvada™ as PrEP (e.g., daily dosing schedule, side effects)
Population-specific barriers and stigma
Lack of gender-affirming healthcare for transgender women
Lack of trans-inclusive marketing of PrEP
Low prioritization of PrEP for people who inject drugs
Stigma associated with PrEP use and accessing HIV services
The intersection of HIV-stigma with transphobia and homophobia
Communication and awareness
Community-engagement and community-mobilization strategies
Systems to improve interagency/interprofessional collaboration
General advocacy for expanded health insurance
Funding for medication costs, adherence counseling/monitoring, and support services; referral to medication-assistance programs
Capacity and access
Expanded PrEP-delivery systems, staff, time, space, expertise
Engagement of generalist PCPs in PrEP provision for scale-up (addressing the purview paradox)
Expanded/diversified settings providing PrEP (e.g., private practices, mental-health clinics, ERs) and integration of PrEP into primary care
Expanded education, screening, referrals to PrEP services
Improved methods to identify appropriate PrEP candidates
Specific guidelines from “normative bodies” (e.g., CDC, APA)
Partnerships between medical and social-service providers
Development of systems to monitor and evaluate PrEP use
Cross-training of staff (e.g., educators, pharmacists, nurses)
Improvements in pharmacists’ PrEP education
Advancing new PrEP technologies: innovative pharmacologic chemoprophylactic approaches (e.g., on-demand PrEP dosing, injectable, microbicides, rings, films)
Pharmacokinetic studies of potential drug–drug interactions, particularly in oral PrEP medications and feminizing hormones
Population-specific barriers and stigma
Disaggregating transgender women from MSM in research and clinical practice and developing trans-inclusive research strategies
Improving access to trans-competent PrEP providers
Integrating PrEP care with contraceptive services
Focusing resources on vulnerable communities
Expanded “youth-friendly” health services, including augmented PrEP visit schedules, adherence clubs and social-support groups
The final set of articles (n = 47) included four broad categories of papers: primary data on cognitive variables (e.g., perspectives, beliefs, and concerns) of HIV-prevention providers (n = 18) [9, 14, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45]; primary data on cognitive variables and perspectives of individuals considered at risk for HIV infection (n = 9) [46, 47, 48, 49, 50, 51, 52, 53, 54]; reviews of current literature on PrEP implementation (n = 16) [10, 11, 17, 19, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66]; and case studies of PrEP demonstration and implementation projects (n = 4) [12, 54, 67, 68]. From the text of these articles, we extracted and recorded key barriers to implementation and the interventions proposed to address them. Then we mapped out the barriers. Among patients and providers, we identified cognitive barriers and interventions regarding their knowledge, attitudes, and beliefs about PrEP. Barriers involving healthcare systems included communication and awareness about PrEP, lack of funding and/or insurance, and capacity and access. We also identified pharmaceutical- and population-specific barriers. Below we provide an account of these barriers and the interventions that might address them, thus improving PrEP implementation. Table 1 provides a summary of these findings.
Barriers to and Interventions with Potential to Improve PrEP Implementation
Individual and Relationships Domains—Provider Level
Eighteen articles focused on primary care physicians, HIV and infectious-disease specialists, pharmacists, and nurse practitioners—including analyses of focus groups, interviews, and surveys. None of the papers included data from social-service providers, though most of them mentioned the need for the expansion of referrals to mental-health and other support services, care coordination, and peer-based groups, all of which might improve PrEP implementation [10, 30, 32, 46, 57, 66]. Providers described concerns and solutions across socioecological levels. For instance, proposed system-level solutions included engaging generalist physicians in PrEP provision , community education campaigns , and increased funding for counseling and social support services .
Significantly, many of these papers noted the “purview paradox”—the idea that the providers who are best trained and most willing to prescribe PrEP (i.e., HIV specialists) often do not see HIV-negative patients who would benefit from PrEP, while physicians who regularly care for HIV-negative patients (i.e., primary care physicians) are often not trained to provide PrEP [14, 56]. Other barriers included providers’ lack of knowledge, negative attitudes toward PrEP, lack of training in PrEP provision, disagreements about who might be appropriate candidates for PrEP use, and concerns about insurance coverage for PrEP. The solutions proposed to address knowledge gaps included trainings and interventions to assist providers in identifying appropriate PrEP candidates. We also found that prejudicial beliefs (e.g., assessments of the likelihood of risk behavior based on race) , concerns about the efficacy (or “real world” efficacy) of PrEP, toxicities, and future resistance, and about patients’ behavior (e.g., sexual risk and lack of adherence) were often reported as substantial barriers to PrEP implementation .
Individual and Relationships Domains—Patient Level
Nine articles reported on primary data about potential PrEP patients’ attitudes, beliefs, and experiences. Most included qualitative interviews and results of focus groups with community members. We considered data from provider perspectives on patient-level barriers and solutions—for example, perceived barriers regarding increased risk behaviors associated with PrEP use. Barriers cited included patients’ lack of knowledge and low demand for PrEP, as well as socioeconomic (e.g., stigma and difficult access to transportation) and medical burdens (e.g., side effects of PrEP) that complicate PrEP uptake. Perceived barriers, some not confirmed by strong evidence, included concerns about effectiveness , toxicities [11, 14, 32, 69], and interactions with gender-affirming hormones among transgender women [56, 62]. Research cited the higher priority given to care for current conditions, both medical and psychosocial, and gender-affirming hormone therapy than to HIP [46, 48, 49]. The “seasonal” nature of sexual risk trajectories was also reported as a barrier to PrEP . Distrust of the medical system based on historical legacies of structural racism, transphobia, and other forms of discrimination was reported as a significant barrier to PrEP access [10, 62].
The review also revealed a diminished concern about HIP when patients are in intimate partnerships and/or using substances [46, 49], an unwillingness to discuss PrEP with primary care providers, and challenges managing multiple health concerns, in addition to potential side effects from PrEP. While many of these barriers focused on the patient, we found that proposed interventions often necessitated system-level interventions (e.g., expanded access to and capacity for PrEP and targeted interventions to address population-specific barriers to PrEP). Individual-level solutions proposed included targeting knowledge and awareness, attitudes, beliefs, and burdens; focusing on increased education and counseling; and offering supportive behavioral interventions such as risk reduction, medication adherence, and retention counseling [12, 17, 50, 56]. Interventions were proposed to help patients navigate healthcare systems and improve the frequency of referrals to mental health, substance abuse, and other supportive services.
Community and Policy Domains—Healthcare-System Level
Twenty studies consisted of broad reviews of existing PrEP literature or reviews of large-scale PrEP demonstration or implementation projects. These studies, as well as those focused on provider and potential-patient perspectives, addressed myriad system-level barriers to PrEP implementation and proposed system-level solutions. We organized the system-level barriers into five categories: problems with communication and awareness; lack of funding and/or insurance; lack of capacity and access; pharmaceutical barriers; and population-specific issues and stigma.
Problems with Communication and Awareness
Our review revealed a lack of effective messaging about PrEP and communication between healthcare providers and community-based organizations . Proposed solutions in this domain included community engagement and mobilization strategies  as well as systems to improve interagency and interprofessional collaboration.
Funding and/or Insurance Barriers
Lack of funding is the most consistently cited system-level barrier, including limited health budgets to sustain PrEP programs and lack of insurance coverage [9, 46, 47, 54, 56]. The latter has been framed as both a systems-level barrier to access and care, with studies showing that patients without access to insurance are less likely to successfully obtain PrEP ; and as a provider-level barrier, with insurance barriers affecting providers’ attitudes and behaviors about prescribing PrEP . The cost of PrEP is covered by many health insurance plans . Gilead Advancing Access® program, a commercial medication assistance program, provides free PrEP to eligible HIV-negative adults in the US with limited income and no insurance covering PrEP . However, individuals enrolled in government programs (e.g., Medicare Part D, Medicaid, TRICARE, or VA) are not eligible for this program. Adolescents under 18-years-old and young people covered by their parents’ insurance, and who may wish to seek PrEP independently to avoid disclosure through their parents’ Explanation of Benefits, are also excluded from this program [65, 66, 72]. Private insurers’ policies concerning medications, including PrEP, are insurance-specific and thus outside the scope of this review. However, it is important to mention that insurers have enacted policies that may exacerbate existing barriers to PrEP implementation, such as prior authorization paperwork requirements, and strict requirements regarding completion of test results prior to authorizations and prescription renewals. In addition to suggesting help for patients in navigating healthcare systems to access insurance and co-pay assistance programs, articles proposed general advocacy for expanded health insurance , coverage of medication costs, PrEP adherence counseling, and support services .
Capacity and Access
Barriers included a lack of focus on non-prescribing providers ; the purview paradox; lack of referral systems, and lack of training on, for example, when to initiate PrEP; legal constraints to providing PrEP for youth ; lack of access to care caused by inadequate transportation, inflexible work schedules, time constraints during medical appointments , and inconvenience of locations dispensing PrEP; and lack of medical insurance. Solutions to these barriers included expanded space, time, and expertise for PrEP-delivery systems ; engagement of generalist PCPs in PrEP provision (to address the purview paradox); diversification of settings providing PrEP (e.g., mental-health clinics and criminal-justice settings) ; integration of PrEP into primary care; education, screening, and referrals to PrEP; improved methods to identify appropriate PrEP candidates ; stronger guidelines and policies for providers ; partnerships between medical and social-service providers; cross-training of staffers (e.g., social workers, educators, pharmacists, and nurses); leadership support of increased staff time to address financial barriers ; and improving pharmacists’ PrEP education .
We identified barriers specific to Truvada™ and its oral daily dosing schedule and potential side effects. Proposed solutions included advancing new PrEP technologies, such as pursuing innovative pharmacologic chemoprophylactic approaches (e.g., on-demand PrEP dosing, injectables, microbicides, rings, and films), and pharmacokinetic studies of potential drug–drug interactions, particularly involving those with feminizing hormones [11, 62].
Population-Specific Issues and Stigma
Several papers focused on transgender women [49, 53, 62], Black and Latina women , Black and Latino MSM , adolescents [65, 66], men who engage in street-based sex work , heterosexual couples , and people who inject drugs [43, 63]. These papers point to stigma associated with PrEP use and the intersection of HIV-stigma with transphobia and homophobia [48, 49]. Despite the number of articles that identify stigma as a barrier to PrEP, few interventions were proposed that would directly address the effects of stigma.
Barriers specific to transgender women included non-inclusive marketing of PrEP; perceived interactions with feminizing hormones and prioritization of hormone care; managing multiple medical appointments and medications; mistrust arising from transphobia in the medical system; and life instabilities and substance use. Proposed gender-affirming healthcare initiatives included prioritizing hormones and gender-affirming medical care, exclusively using patients’ preferred names and pronouns, and creating safe spaces for trans clients . Studies also proposed pharmacokinetic studies of potential drug–drug interactions between oral PrEP medications and gender-affirming hormones in transgender women [11, 62]. Sevelius et al.  argue that current deficits in the provision of gender-affirming care for transgender women are connected to the conflation of transgender women with MSM, which serves to conceal transgender women’s unique social and behavioral vulnerabilities.
Cisgender Black Women and Latinas
Like transgender women, cisgender Black women and Latinas face particular barriers to engaging with messages often designed for MSM . PrEP implementation among women may be helped by addressing the burden of frequent medical visits; the stigma associated with accessing HIV services; and the burden of pill-taking, including concerns about adding to an existing pill burden. Increasing the availability of PrEP in settings where women receive services may also improve PrEP uptake, for example by integrating PrEP care with provision of contraceptives and screening for sexually transmitted infections .
Black and Latino Men
Barriers for Black and Latino men include decreased access to private health insurance and more access through public clinics, as well as frequently endorsed stigma-related concerns about PrEP [47, 51]. Healthcare is a problematic area for MSM of color, who are more likely than other men to view talking about their sex lives to their doctors as a barrier to PrEP . Moreover, research included in this review indicates that medical providers in training exhibit prejudicial assessments of Black patients based on stereotypes about risk compensation (e.g., increased condomless sex associated with PrEP use) . While this study was limited to current medical students, exploratory research surveying medical providers (primarily HIV specialists) suggests that providers’ likelihood to prescribe PrEP varies widely across patient groups, making the potential consequences of prejudicial assessments particularly troubling . These barriers underscore the limitations and potentially severe consequences of considering seemingly individual-level interventions (such as provider knowledge or individual behavior) in isolation from larger systemic factors, such as structural racism.
The purpose of this integrative review was to identify barriers to PrEP implementation and interventions to improve it. The 47 reviewed articles reported barriers at all four domains of the conceptual framework. But these barriers rarely exist in isolation, and proposed interventions are not always aligned to specific barriers. For instance, while a number of papers (n = 18) focused exclusively on the perspectives, knowledge, and concerns of providers, these papers rarely offered solutions to overcome barriers related to providers; instead, they offered solutions focused on targeting the behavior of individual patients, such as interventions to improve patient adherence  or evidence-based interventions to reduce risk compensation . Moreover, frequently cited barriers to PrEP implementation cut across all three levels, as in the case of the purview paradox [14, 56], and also in the case of structural barriers, such as patient distrust of the medical system based on historical legacies of structural racism and of transphobia [10, 62]. Grounded in our understanding of this literature, we provide a comprehensive picture of how potential changes to PrEP implementation can be mapped onto specific barriers identified in the extant literature. In so doing, we are filling a research gap in the literature.
Given the interconnected nature of the barriers identified, we recommend the adoption of a dynamic social-systems model, as developed by Latkin and colleagues, for PrEP implementation in which individual, dyad, and structural factors are viewed as elements of a complex system in which none functions in isolation (p. S233) . We also suggest (below) specific targets of interventions based on Nunn et al.’s nine-step PrEP care continuum, analogous to the HIV Continuum of Care, as a model for PrEP implementation—identifying individuals at high risk, increasing individual HIV-risk awareness, enhancing PrEP awareness, facilitating PrEP access, linking to PrEP care, prescribing PrEP, initiating PrEP, adhering to PrEP, and retaining individuals in PrEP care . Both these models suggest multilevel interventions to achieve effective PrEP implementation. Multilevel interventions would integrate biomedical, behavioral, and structural or systemic components . Just as patients, providers, and systems do not operate in isolation, proposed interventions cannot be considered to perform isolated functions (e.g., biomedical, behavioral, or structural).
“PrEP navigation”—auxiliary, non-prescribing providers whose role is to assist people in overcoming structural barriers to care  is an intervention whose potential to address barriers in different socioecological domains has been acknowledged. The National Institutes of Health (NIH) has submitted requests for proposals for PrEP implementation programs, including a call for “PrEP navigator resource development and dissemination” . A search of the NIH U.S. National Library of Medicine reveals four clinical trials involving PrEP navigators  and the NIH Research Portfolio Online Reporting Tools (RePORT) reveals six projects on PrEP navigation for Black MSM, young Latino MSM, women upon release from incarceration, people who inject drugs (PWID), and methamphetamine users . Though promising, PrEP navigation is not likely to address many of the barriers identified by this review—for example; at the Individual and Relationships Domains, primary care providers’ lack of knowledge in identifying PrEP candidates and prescribing PrEP; and, at the systems level, lack of funding and insurance, and stigma.
Therefore, the combination of and future testing of the effect of additional interventions is recommended. Clinic-based interventions should include trainings to assist both HIV-prevention and HIV-care providers in identifying appropriate PrEP candidates. Such training must target knowledge development (e.g., concerns about “real world” efficacy, toxicities, and future resistance); attitudes (e.g., prejudicial beliefs and assessments of the likelihood of risk behavior based on race or gender identity); and social norms about patients’ behavior (e.g., sexual risk and lack of adherence). Though provider training may improve PrEP implementation, system-level interventions (e.g., clinic funding and capacity) are needed to address population-specific barriers . Navigation suggests help for patients in navigating healthcare systems to access insurance and co-pay assistance programs; nonetheless, system-level advocacy is also needed for expanding health insurance, coverage of medication, PrEP adherence counseling, and support services. Furthermore, interventions that directly address the effects of race- and gender-related stigma and racism may improve participation of underserved groups (e.g., Black MSM and transgender women) in the HIV Continuum of Care and thus their access to PrEP.
Our approach and analysis highlight the structural dimensions of barriers to healthcare and public health and are consistent with literature addressing tensions between individual- and system-level barriers , structural stigma , and the shift from models of “cultural competency” to “structural competency” . One possible limitation of our search terms is that we did not use the less common variation “preexposure prophylaxis,” and some papers using such term may have been missed. Nonetheless, based on our search, we identified, categorized, and analyzed barriers to PrEP implementation and interventions at the patient, provider, and healthcare-system levels. We argue for multilevel interventions that do not target providers, patients, or systems in isolation, but rather incorporate each of these levels into new models of implementation. We understand that our suggestion that interventions target all three areas is challenging, especially with regard to healthcare systems. As we know from current political discourse, healthcare systems are difficult to change and must be viewed in the context of larger political and structural realities that are challenging at best and nearly impossible to navigate at worst. An awareness of the challenges of healthcare systems, and the provision of concrete solutions for those needing and seeking PrEP, can be valuable means of improving healthcare-system interventions. Without attention to the ways structural factors affect individuals within healthcare systems, PrEP implementation may actually reinforce existing inequities that place the overwhelming burden of the HIV epidemic on more-vulnerable groups.
There is no funding attached to this manuscript.
Compliance with Ethical Standards
Conflict of interest
Rogério M. Pinto declares that he has no conflict of interest. Kathryn Berringer declares that she has no conflict of interest. Rita Melendez declares that she has no conflict of interest. Okeoma Mmeje declares that she is a paid consultant (i.e., detailee) for the CDC Program Development and Quality Improvement Branch of the National Center for HIV/AIDS, Viral Hepatitis, STD and TB.
Human and Animal Rights
No animals or humans were involved in this research.
- 4.World Health Organization, Clinical Guidelines Across the Continuum of Care: Linking people diagnosed with HIV infection to HIV care and treatment, in Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach June 13. 2013, World Health Organization: Geneva, Switzerland. p. 272.Google Scholar
- 5.CDC, High-impact HIV prevention: CDC’s approach to reducing HIV infections in the United States. 2011, Centers for Disease Control & Prevention National Center for HIV/AIDS VH, STD, and TD Prevention, Division of HIV/AIDS Prevention.Google Scholar
- 10.Wilton J, et al. Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. HIV/AIDS (Auckland, NZ). 2015;7:125.Google Scholar
- 27.FDA, FDA approves first medication to reduce HIV risk. Silver Spring; 2012.Google Scholar
- 29.Strauss A, Corbin JM. Basics of qualitative research: Grounded theory procedures and techniques. Thousand Oaks: Sage Publications; 1990.Google Scholar
- 65.Burda JP. PrEP and our youth: implications in law and policy. Columbia J Gender Law. 2015;30:295.Google Scholar
- 70.Centers for Disease Control and Prevention. PrEP. 2018; https://www.cdc.gov/hiv/basics/prep.html.
- 71.Gilead Sciences Inc. Gilead Advancing Access. 2018; https://www.gileadadvancingaccess.com/.
- 76.NIH. NLM Requests Quotations for 2017 HIV/AIDS Community Information Outreach Projects. 2017 June 01, 2017 March 27, 2018; https://www.nlm.nih.gov/news/nlm_rfq_hiv_aids_outreach_2017.html.
- 77.Medicine U.S.N.L.o. ClinicalTrials.gov Database. https://clinicaltrials.gov/.
- 78.US Department of Health and Human Services, Research Portfolio Online Reporting Tools (RePORT).Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.